Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials

OBJECTIVE: EMBODY 1 (ClinicalTrials.gov identifier: NCT01262365) and EMBODY 2 (ClinicalTrials.gov identifier: NCT01261793) investigated the efficacy and safety of epratuzumab, a CD22‐targeted humanized monoclonal IgG antibody, in patients with systemic lupus erythematosus (SLE). The studies showed n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottenberg, Jacques‐Eric, Dörner, Thomas, Bootsma, Hendrika, Devauchelle‐Pensec, Valérie, Bowman, Simon J., Mariette, Xavier, Bartz, Holger, Oortgiesen, Marga, Shock, Anthony, Koetse, Willem, Galateanu, Catrinel, Bongardt, Sabine, Wegener, William A., Goldenberg, David M., Meno‐Tetang, Guy, Kosutic, Gordana, Gordon, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947119/
https://www.ncbi.nlm.nih.gov/pubmed/29381843
http://dx.doi.org/10.1002/art.40425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947119/
https://www.ncbi.nlm.nih.gov/pubmed/29381843
http://dx.doi.org/10.1002/art.40425

Ejemplares similares